Overview

Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis

Status:
Recruiting
Trial end date:
2025-05-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate plaque psoriasis and special site involvement.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC